Home ›
Stock Message Boards ›
Stock Boards ›
OWC Pharmaceutical Research Corp. (OWCP) Message Board

The two newest advisors have a lot of experience i

Message Board

Public Reply |

Private Reply |

Keep |

Replies (1)

Post New Msg

Edit Msg () |

Previous

| Next

Post# of 15624

(Total Views: 314)

Posted On: 03/06/2017 5:06:30 PM

Posted By: Triple9

Re: Ortiz26 #707

The two newest advisors have a lot of experience in skin care, so I think it's highly likely they will do more creams especially after their formulation has passed IRB safety studies.

Quote:
PETACH TIKVA, Israel, February 7, 2017 /PRNewswire/ --

OWC Pharmaceutical Research Corp. (OWCP), ("OWC" or the "Company" , a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced the appointment of Dr. Sharon Rozenblat as Senior Advisor to the Scientific Advisory Board of its wholly-owned Israeli subsidiary, One World Cannabis Ltd ("OWC Israel" .

(Logo: http://mma.prnewswire.com/media/458036/OWC_Logo.jpg)

Dr. Rozenblat will be tasked with overseeing the completion of the pre-clinical safety studies on the Company's treatment for psoriasis, which commenced in November 2016. Dr. Rozenblat will also steer the Company's efforts to commercialize OWC's cannabis-based formulations and delivery mechanisms.

Dr. Yehuda Baruch, OWC's Chief Scientific Officer, commented on the appointment, "Dr. Rozenblat has had a significant impact in the field of dermatology, specifically with regard to botanical formulations. With more than 15 years' experience in the research and development of herbal extracts and related products, as well as considerable experience in the design and management of clinical trials, she is the perfect complement to our scientific team."

From 2007 to 2015, Dr. Rozenblat served as Chief Scientist at Kamedis ltd., an Israeli-based dermatological company, where she had established and managed the research and development of herbal products for the treatment of dermatological conditions.

In addition to her work at Kamedis, Dr. Rozenblat serves as a consultant to international organizations, including as Scientific Research Director of joint development projects funded by the Korea-Israel Industrial Research and Development Foundation (KORIL), and the Israel-Singapore Foundation (SIIRD), both of which resulted in numerous products and patents . Dr. Rozenblat was also the Scientific Director for the development of herbal extraction in a joint venture with Green Mountain Biotech (GMB), in Chengdu, China, where she worked with GMB to find agricultural resources, develop extraction methods, establish quality control methodologies, and conduct safety and efficacy studies.

Mordechai Bignitz, OWC's Chairman and Chief Executive Officer, went on to say, "We could not be happier that Dr. Rozenblat has agreed to join our advisory board. I expect her insight and guidance will prove invaluable as we begin marketing our psoriasis treatment in the second quarter."

Dr. Rozenblat earned her doctorate in Biochemistry and Cell Biology from Bar Ilan University in Israel, where her research focused on botanical components as therapeutic agents for melanoma. She has authored and contributed to numerous papers and is a frequent speaker at dermatological events, including the three most recent American Academy of Dermatology (AAD) annual meetings .